



New Insights in Subunit Vaccines

Guest Editors:

Prof. Dr. Jagannadha Sastry

1. UT Health, MD Anderson
Cancer Center- Graduate School
of Biomedical Sciences, Houston,
TX 77030, USA

2. Department of Thoracic Head
& Neck Medical Oncology and
Department of Comparative
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Dr. Vikas Saxena

Center for Vascular and
Inflammatory Diseases,
University of Maryland School of
Medicine, Baltimore, MD 21201,
USA

Deadline for manuscript
submissions:

closed (30 June 2022)

Message from the Guest Editors

Dear Colleagues,

Our Special Issue focuses on subunit vaccines. Subunit vaccines differ from inactivated whole-cell vaccines, as they contain only antigenic parts of the pathogens necessary to elicit a protective immune response. By using recombinant proteins, subunit vaccines can be manufactured in a large volume at low cost. While subunit vaccines induce immune response, a generation of long-lasting immunologic memory remains a point of concern.

To address these issues, antigenic properties of potential subunits of a pathogen need examination, and an understanding of particular combinations for effective, long-lasting immune response is needed. Therefore, in this Special Issue, we invite you to submit an original research or review manuscript. Articles related to development of a safe, practical, and effective subunit-based vaccine discussing identification of target antigen, adjuvant, and carrier, manufacturing of recombinant antigen, immunological responses, and testing of candidate vaccine efficacy in animal and clinical trials fall under the scope of this issue.

We look forward to publishing your exciting research.

Prof. Dr. Jagannadha Sastry

Dr. Vikas Saxena

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com